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Background: Comprehensive analyses
have shown that screening for cancer
usually induces net costs. In this study,
the possible costs and savings of endo-
scopic colorectal cancer screening are
explored to investigate whether the in-
duced savings may compensate for the
costs of screening. Methods: A simula-
tion model for evaluation of colorectal
cancer screening, MISCAN–COLON,
is used to predict costs and savings for
the U.S. population, assuming that
screening is performed during a period
of 30 years. Plausible baseline param-
eter values of epidemiology, natural
history, screening test characteristics,
and unit costs are based on available
data and expert opinion. Important pa-
rameters are varied to extreme but
plausible values. Results: Given the ex-
pert opinion-based assumptions, a pro-
gram based on every 5-year sigmoidos-
copy screenings could result in a net
savings of direct health care costs due
to prevention of cancer treatment costs
that compensate for the costs of screen-
ing, diagnostic follow-up, and surveil-
lance. This result persists when costs
and health effects are discounted at
3%. The “break-even” point, the time
required before savings exceed costs, is
35 years for a screening program that
terminates after 30 years and 44 years
for a screening program that continues
on indefinitely. However, net savings
increase or turn into net costs when al-
ternative assumptions about natural
history of colorectal cancer, costs of
screening, surveillance, and diagnostics
are considered. Conclusions: Given the
present, limited knowledge of the dis-
ease process of colorectal cancer, test
characteristics, and costs, it may well
be that the induced savings by endo-
scopic colorectal cancer screening com-
pletely compensate for the costs. [J Natl
Cancer Inst 2000;92:557–63]
In the past, it has often been asserted
that preventive medical services, includ-
ing screening, are cost saving. The use of
preventive services has sometimes been
promoted to reduce health care costs.
However, this claim generally has not
been supported by detailed analysis. For
instance, most well-conducted cost-
effectiveness analyses of breast and cer-
vical cancer screening find that the costs
of screening tests, of diagnostic follow-
up, and of treatment are much larger than
the savings in treatment costs (1–3).
Colorectal cancer is an important
health problem in industrialized countries
and comprises 11% of all cancer inci-
dence and 13% of all cancer mortality in
the United States (4). Several modalities
have been proposed to screen for this dis-
ease, including fecal occult blood test,
flexible sigmoidoscopy, double-contrast
barium enema, and colonoscopy (5,6).
Three fecal occult blood test trials using
Hemoccult tests have shown a reduction
in colorectal cancer mortality (7–10).
Economic evaluations linked to two of
these trials have concluded that screening
by fecal occult blood test is likely to be
cost-effective but not cost saving (11,12).
Cost-effective means that the incremental
cost of obtaining a unit of health effect
from screening compared with no screen-
ing is below an accepted benchmark,
while cost-saving interventions result in a
net economic savings as well as a savings
in quality-adjusted life-years (13). The ef-
ficacy [i.e., the extent to which medical
interventions achieve health improvement
under ideal circumstances (13)] of endo-
scopic or barium enema screening has not
yet been demonstrated by randomized
controlled trials, although several case–
control studies (14–18) suggest that endo-
scopic screening is associated with a sub-
stantial reduction in mortality from
colorectal cancer. One reason that screen-
ing by endoscopy has been proposed as a
supplement or alternative to fecal occult
blood test screening is that the preventive
effect of the former is likely to be larger.
Invasive cancer and its associated high-
treatment costs may be prevented through
detecting and removing noninvasive ade-
nomas that are generally believed to be
precursors of colorectal cancer. The re-
sults of ongoing endoscopic trials are ex-
pected to become available in several
years and will provide more definitive in-
formation on the magnitude of this pre-
ventive effect (19–21). In this study, we
estimate the costs and savings of endo-
scopic screening by use of a simulation
approach.
METHODS
The results are based on simulation outcomes of a
detailed model for evaluation of colorectal cancer
screening (MISCAN–COLON) that has been devel-
oped by the Department of Public Health at the Eras-
mus University Rotterdam, The Netherlands, in co-
operation with the National Cancer Institute (NCI)
in the United States (22). The model is an adapted
version of a microsimulation model previously used
for the evaluation of breast and cervical cancer
screening (1,23–26). At two expert meetings at the
NCI on June 5–7, 1996, and May 12–13, 1997, a
model structure was devised in agreement with the
currently accepted model of the adenoma–
carcinoma sequence (see “Appendix” section for the
participants of the expert meetings). The validity of
this “expert” model is based on observational data,
such as clinical incidence and mortality from colo-
rectal cancer (27) and the size distribution of ade-
nomas in autopsy studies (28–32). The validity of
this model has not been tested on a large longitudi-
nal dataset because that is currently unavailable. A
sensitivity analysis has been carried out for impor-
tant uncertain parameters. If no published data are
available for an estimate of a parameter, the estimate
has been decided on by the expert panel during the
two working meetings that were followed by an e-
mail discussion. Using the MISCAN–COLON
model (22), it is possible to track costs and induced
savings in a hypothetical screening program over an
extended period of time.
In the following section, the structure of the ex-
pert model, the initial model parameter values, and
the assumptions in the alternative variants are pre-
sented.
Affiliations of authors: F. Loeve, R. Boer, M. van
Ballegooijen, G. J. van Oortmarssen, J. D. F.
Habbema, Department of Public Health, Erasmus
University Rotterdam, The Netherlands; M. L.
Brown, Applied Research Branch, Division of Can-
cer Control and Population Sciences, National Can-
cer Institute, Bethesda, MD.
Correspondence to: F. Loeve, M.S., Department
of Public Health (iMGZ), Medical Faculty, Erasmus
University Rotterdam, P.O. Box 1738, 3000 DR
Rotterdam, The Netherlands (e-mail: loeve@mgz.
fgg.eur.nl).
See “Notes” following “References.”
© Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 7, April 5, 2000 REPORTS 557
Expert Model
Structure of the model. In the microsimulation
model, persons are simulated in whom one or more
colorectal neoplastic lesions may develop. Each le-
sion is simulated separately, enabling each lesion to
have its own natural history. Every lesion is located
at a specific site in the colorectal tract, thus enabling
simulation of the reach of endoscopic tests.
The disease stages that are distinguished in the
adenoma–carcinoma sequence are shown in Fig. 1.
The adenomas are categorized into size categories:
less than or equal to 5 mm, 6–9 mm, and greater than
or equal to 10 mm. Most of the adenomas will never
grow into cancer in a lifetime. Progressive adeno-
mas will grow into preclinical cancer and will even-
tually be clinically diagnosed, but a person may die
of other causes before that age of clinical diagnosis.
The preclinical and clinical invasive cancer stages
are subdivided into American Joint Committee on
Cancer/International Union Against Cancer stages
I–IV (33). Clinical stage refers to the stage of cancer
that is assigned on clinical detection. Preclinical
stage refers to the stage that would be assigned on
screen detection for a screen-detectable cancer,
whether or not screening actually takes place.
Model of the situation in the absence of screen-
ing. It is assumed that all cancers are preceded by
adenomas. The expert panel agreed on an estimate of
the average sojourn time (i.e., the duration between
onset of a progressive adenoma and the clinical di-
agnosis of subsequent cancer) of 20 years. The av-
erage duration of cancer in preclinical stages I–IV is
2 years, 1 year, 1.5 years, and 0.8 year, respectively,
which results in a total average duration of 3.6 years
because not every cancer reaches stage IV before
clinical diagnosis. These sojourn times are based on
the ratio between the stage-specific detection rate at
first screening in fecal occult blood test trials and the
background incidence, accounting for a 60% sensi-
tivity of fecal occult blood test for all cancer stages
(9,10). All durations are governed by an exponential
probability distribution. Durations in each of the in-
vasive cancer stages as well as durations in the
stages of the noninvasive adenomas are assumed to
be 100% associated with each other, but the dura-
tions in invasive stages as a whole are independent
of durations in noninvasive adenoma stages that may
precede cancer. These assumptions result in an ex-
ponential distribution of the total duration of pro-
gressive noninvasive adenomas and of the total du-
ration of preclinical cancer, which has also been
used in other cancer screening models (34,35). It is
assumed that 30% of the cancers arise from adeno-
mas of 6–9 mm and that 70% arise from larger ad-
enomas.
The preclinical incidence of progressive adeno-
mas has been chosen to reproduce the colorectal
cancer incidence by age, stage, and localization in
the United States in 1978 (27). During this period,
almost no screening was performed. The size distri-
bution of adenomas over all ages is assumed to be
56% for stages less than or equal to 5 mm, 24% for
stages 6–9 mm, and 20% for stages greater than or
equal to 10 mm (28–32). The preclinical incidence
of nonprogressive adenomas that will never grow
into cancer has varied until the simulated prevalence
of all adenomas was about 15% in age group 50–59
years, 27% in age group 60–69 years, and 33% in
age group 70 or more years, in agreement with data
from the Kaiser study in Northern California (36)
and with data from autopsy and colonoscopy studies
(28–32). A good agreement with these data is
achieved when 86% of the adenomas that arise be-
fore age 65 years are nonprogressive and the per-
centage of nonprogressive adenomas arising after
age 65 years decreases gradually to 63% at age 75
years and to 4% at age 100 years. Each individual
is assumed to have one level of risk to develop
both progressive and nonprogressive adenomas.
This risk index follows a gamma distribution where
the variance is twice the mean, which results in an
adenoma frequency distribution found in autopsies
(37).
The anatomic site distribution of both progressive
and nonprogressive adenomas and thus of preclini-
cal and clinical cancers is assumed to be equal to the
site distribution of colorectal cancers in the United
States in 1978 (27). The mortality from other causes
is assumed to be constant across the simulated years
and equal to the mortality in the United States from
1989 through 1991. The stage-specific survival after
the clinical diagnosis of colorectal cancer is taken
from the Surveillance, Epidemiology, and End Re-
sults1 registry data from 1975 through 1993 (27).
Characteristics of screening, surveillance, and
diagnostic tests. The reach of screening sigmoidos-
copy and surveillance colonoscopy is modeled by
use of data from the Kaiser Northern California
screening program (38). The sensitivity of surveil-
lance colonoscopy for each lesion within realized
reach is assumed to be 80% in adenomas less than or
equal to 5 mm, 85% in adenomas 6–9 mm, and 95%
in adenomas greater than or equal to 10 mm and
cancers (39,40). The expert panel decided to assume
the same sensitivity for sigmoidoscopy in lesions
within reach of the test, except for a slightly lower
value of 75% test sensitivity in adenomas less than
or equal to 5 mm. After a positive test, all lesions
will be removed within a short time. The percentage
of the population without adenomas or cancer but
with hyperplastic polyps, lipomas, or other lesions
that lead to polypectomy and pathology after sig-
moidoscopy or colonoscopy has been estimated
from Kaiser data (38): 5% for sigmoidoscopy and
10% for colonoscopy. These percentages are as-
sumed to be independent of the screening round.
Fig. 1. Adenoma and cancer stages
in the MISCAN–COLON micro-
simulation model. Cancer stages
correspond to the American Joint
Committee on Cancer/Interna-
tional Union Against Cancer stag-
ing system for colorectal cancer.
Adenomas are categorized by size.
The size-specific prevalence of ad-
enomas as well as the proportion
of adenomas that ever develop into
cancer is dependent on age. In the
expert model, it is assumed that
the proportion of progressive ade-
nomas increases from 16% at age
65 years, to 37% at age 75 years,
and 96% at age 100 years. In the
expert model, it is assumed that
50% of nonprogressive adenomas
will remain in the 6- to 9-mm
stage until death and 50% will
progress to the greater than or
equal to 10-mm stage. For pro-
gressive adenomas, it is assumed
that 30% will develop through the
sequence less than or equal to 5-mm adenomafi 6- to 9-mm adenomafi preclinical stage I cancer and that 70% will develop through the sequence less than or equal
to 5-mm adenomafi 6- to 9-mm adenoma fi greater than or equal to 10-mm adenomafi preclinical stage I cancer. The mean duration time for progressive adenomas
is assumed to be 16.4 years (with an exponential distribution). The mean duration time for cancer is assumed to be 2 years (stage I), 1 year (stage II), 1.5 years (stage
III), and 0.8 year (stage IV).
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Survival after screen detection. The stage-
specific survival of patients with screen-detected
cancer is assumed to be the same as the survival of
patients with cancers clinically diagnosed in the
same stage (9). Removal of an adenoma always pre-
vents development of any subsequent cancer that
may have arisen from this adenoma. The mortality
from, but not the cost associated with, complications
after colonoscopy is assumed to be negligible, be-
cause data indicate that this mortality is very low
(41).
Unit costs. Published estimates of the cost of
screening flexible sigmoidoscopy range from $58
(42) to $150 (43). The cost of sigmoidoscopy is
assumed in this model to be $100. Estimates of colo-
noscopy without polypectomy range from $150
(12,44) to $1000 (45), while estimates of the cost of
colonoscopy with polypectomy and pathology range
from $150 (12) to $1500 (43). The lower estimates
reflect unit cost as measured in organized European
screening programs or in particular U.S. practices
that have placed a premium on achieving efficient
delivery of endoscopic procedures. The higher esti-
mates are based on submitted charges in conven-
tional practice settings, a source of data that are
generally believed to overstate true costs. In this
model, the cost of colonoscopy without polypecto-
my is assumed to be $300 and the cost of colonos-
copy with polypectomy and pathology is $400. The
rate of nonfatal complications by bowel perforation
is assumed to be two per 1000 colonoscopies per-
formed (45,46), and a perforation induces $30 000
extra costs (41,43).
The treatment costs of cancer are divided into
three categories: 1) the costs for primary cancer
treatment in the first 6 months ($25 000), 2) the costs
of continuous care after primary treatment ($2200
per year), and 3) the costs of terminal care before
death from colorectal cancer ($16 000 in the last 6
months) on the basis of health maintenance organi-
zation data (47). Treatment costs of adenomas found
during screening or surveillance are assumed to con-
sist only of costs for polypectomy and pathology,
thus incorporated in costs of diagnostic or surveil-
lance colonoscopy. All costs are expressed, in real
terms, in 1993 U.S. dollars; therefore, future costs
are not inflated. Discounting, to convert future ex-
penditures to present value, is performed at an an-
nual discount rate of 3%, as recommended by the
Panel on Cost-Effectiveness in Health and Medi-
cine; i.e., dollars expended n years in the future are
discounted by a factor of : 1/(1.03)n (13,48).
Screening strategy. Calculations are made for
sigmoidoscopy screening, delivered at 5-year inter-
vals between the ages of 50 and 75 years, i.e., six
screenings. All positive screening tests are followed
by a diagnostic colonoscopy. If no lesions or only
adenomas less than or equal to 5 mm are found, a
person will again be screened by sigmoidoscopy af-
ter 5 years. Persons in whom adenomas greater than
or equal to 6 mm are found are invited for surveil-
lance colonoscopy after 5 years, and surveillance is
repeated until no lesions are found. Thereafter, one
is screened according to the normal screening strat-
egy.
Costs and savings. Costs and savings are calcu-
lated per person in a simulated dynamic population.
The screening program is in operation from 1993
through 2023. Before 1993, individuals are simu-
lated as described previously in the paragraph en-
titled “Model of the situation in the absence of
screening.” The simulated 1993 age distribution cor-
responds to the U.S. 1993 age distribution (27). No
births take place after 1993. All screening effects are
accounted for by continuing the simulation until all
individuals have died. The savings of primary treat-
ment, continuous care, and terminal treatment are
calculated as the difference in total costs of treat-
ment of clinically diagnosed and screen-detected
cancer in the situation with and without screening.
Model Variants
The impact of changes in major model assump-
tions on results is assessed in a sensitivity analysis
(Table 1). It is not clear whether all cancers are
preceded by adenomas or if some lesions grow di-
rectly into cancer without a preceding adenoma.
Furthermore, the mean and variance of the dwelling
time between onset of a progressive adenoma and
clinical cancer are uncertain. Therefore, in one
model variant, no variation is assumed in duration
between the onset of a progressive adenoma and the
clinical diagnosis of cancer, i.e., a fixed sojourn time
of 20 years. In the other model, the average duration
between the onset of a progressive adenoma and the
clinical diagnosis of cancer of 20 years is changed to
10 years, and the percentage of cancers preceded by
adenomas is decreased from 100% to 70%. The pre-
clinical incidence of nonprogressive adenomas has
been chosen to simulate the same adenoma preva-
lence and colorectal cancer incidence as in the basic
expert model. The costs of screening and surveil-
lance procedures are varied to 50% and 200% of the
expert estimate because of the large range of pub-
lished cost estimates.
RESULTS
In the first years of the screening pro-
gram starting in 1993, approximately 50
individuals per 1000 in the U.S. popula-
tion are screened, and the induced costs of
sigmoidoscopy screening are $8500 per
year per 1000 individuals in the popula-
tion. Screening reduces the incidence in
2023 in the age group 50–84 years from
198 to 105 cases per 100 000 person-
years, while mortality is reduced from 83
to 37 per 100 000 person-years. In the first
years, the induced savings are negligible,
and extra treatment costs are induced by
the early detection of cancer. Later, treat-
ment costs are saved because of preven-
tion of cancers by removal of adenomas
during screening. From the 5th year of the
program onward, the yearly treatment
costs with screening are lower than the
treatment costs without screening. When
the screening program finishes in year 30,
“break-even” occurs by year 35: Cumula-
tive undiscounted costs will be balanced
by savings (Fig. 2). In the years after ces-
sation of the program, screening costs
have stopped, while treatment costs will
still be saved. However, in a program of
continuing screening, the break-even
point will not be reached until the 44th
year of the program, as shown in Fig. 2.
Table 2, A, shows that the 3% dis-
counted costs of a 30-year program of ev-
ery 5-year sigmoidoscopy screenings in
the U.S. population are compensated by
induced savings in a population setting,
resulting in net costs of −$5 per person in
the 1993 U.S. population. The costs in-
volved in screening primarily consist of
the costs of screening sigmoidoscopies,
diagnostic colonoscopy after a positive
test, and costs of surveillance after polyp-
ectomy. A large amount of costs are saved
by the removal of a high-risk noninvasive
adenoma and the prevention of subse-
quent cancer. For example, for a cohort of
50-year-old persons screened until death,
the average undiscounted costs of every
5-year sigmoidoscopy screenings are
$743 per person: $508 generated by
screening tests, $179 by diagnostic tests,
and $56 by surveillance. The average per-
person savings in treatment are $1121:
$629 saved in primary therapy, $271 in
continuous care, and $221 in palliative
care. Table 2, A, shows comparable re-
sults, averaged across all individuals in
the entire U.S. population and discounted
at 3% per year. Discounted per person
costs averaged over the entire population
are as follows: $129 generated by screen-
ing tests, $67 by diagnostic tests, and $12
by surveillance, for a total cost of $208.
Savings in treatment are $213: $128
saved in primary therapy, $39 in continu-
ous care, and $46 in palliative care.
Table 1. Assumptions in expert model and assumptions in alternative models
Expert model
Alternative
assumption
Dwelling time probability distribution type Exponential Constant
Mean dwelling time between onset and clinical diagnosis of cancer 20 y 10 y
Percentage of cancers preceded by an adenoma 100% 70%
Unit cost of sigmoidoscopy $100 $50, $200
Unit cost of colonoscopy without polypectomy $300 $150, $600
Unit cost of colonoscopy with polypectomy $400 $200, $800
Journal of the National Cancer Institute, Vol. 92, No. 7, April 5, 2000 REPORTS 559
Table 2, B, shows the 3% discounted
costs and savings of alternative model
variants. Compared with the expert
model, the savings of treatment in the
variant with a constant sojourn time (20
years) are doubled, resulting in increased
cost savings from screening from $5 to
$236. This is caused by the absence of
fast-growing adenomas that have only a
small chance to be detected by screening.
In the expert model with exponentially
distributed sojourn times, 26% become
cancerous within 5 years. In contrast, with
a constant sojourn time assumption (an
extreme example of a situation with less
variability in dwelling times than in the
expert model), all progressive lesions are
present as noninvasive adenomas for 16
years. In these years, an adenoma can be
detected by up to three screening oppor-
tunities.
In the variant that assumes a mean
value of 10 years for the exponentially
distributed sojourn time and assumes that
only 70% of the cancers are preceded by
an adenoma, the induced savings of treat-
ing cancers are lower than in the expert
model because sigmoidoscopy has less
chance to detect a precancerous lesion be-
fore it develops into preclinical cancer. In
this variant, 70% of the costs of screen-
ing, surveillance, and diagnostic tests are
compensated for by induced savings, and
the net costs are positive (+$58). Clearly,
the outcomes are sensitive to assumptions
about the natural history of the adenoma–
cancer sequence.
In the variant with lower unit costs of
screening, surveillance, and diagnostic
tests, the total induced costs are lower
than those in the expert model, resulting
in increased cost savings compared with
the base case. In the variant with higher
screening costs, the total induced costs are
almost doubled, and only 55% of the in-
duced costs by screening, surveillance,
and diagnostic tests are compensated for
by the induced savings.
DISCUSSION
The results of this study are meaning-
ful because similar analyses of screening
programs for breast and cervical cancers
(1,2) have not demonstrated potential cost
savings under any reasonable set of as-
sumptions. The different results for colo-
rectal cancer screening follow for at least
two reasons. First, the cost of colorectal
cancer treatment is much higher than an
endoscopic procedure during which ade-
nomas can be removed. Therefore, the po-
tential savings for an individual in whom
colorectal cancer is prevented because of
endoscopy are large, in contrast with
breast cancer screening where all targeted
lesions are cancerous and require exten-
sive cancer treatment. Second, the inci-
dence of colorectal cancer is relatively
high and thus the number of preventable
cancers is considerable, unlike the case of
cervical cancer, where the background in-
cidence is low, at least in industrialized
countries where screening is most active.
In screening, costs are induced a num-
ber of years before the potential savings
in treatment. Discounting reduces the
weight of future savings of preventive
measures relative to the costs of the inter-
vention. Therefore, discounted net cost
savings are achieved only if the undis-
counted savings are considerably larger
than the costs. Endoscopic colorectal can-
cer screening might be one instance of
secondary prevention where the 3% dis-
counted induced savings are of the same
magnitude or even larger than the induced
costs. A discount rate of 3% is recom-
mended by the Panel on Cost-Effective-
ness in Health and Medicine. The net
costs per person in the baseline model
change to −$146 with 0% discounting and
to $28 with 5% discounting.
Our analysis assumes stability of im-
portant model parameters over an ex-
tended period of time. If changes in
Fig. 2. Expert model results
of every 5-year sigmoidos-
copy screenings: cumula-
tive undiscounted costs and
savings as a function of pro-
gram years of operation.
Break-even (costs 4 sav-
ings) occurs at year 35 for a
program that terminates
screening at year 30. Break-
even occurs at year 44 for a
program that continues
screening indefinitely.
+++++ 4 cumulative costs
of screening, diagnostics,
and surveillance of an on-
going program; — — 4
cumulative difference in treatment costs for screening compared with no screening; ....... 4 net total costs of
an ongoing program; and ____ 4 net total costs of a program that terminates screening after year 30.
Table 2. Three percent discounted induced costs and savings of every 5-year sigmoidoscopy screening in
age group 50–75 years from 1993 through 2023 per person in the total U.S. population in 1993*
A. Expert model results
Costs of screening, $ 129
Costs of colonoscopic diagnostics during screening, including polypectomy
and complications, $
67
Costs of surveillance, including polypectomy and complications, $ 12
Total induced costs, $ (95% CI) 208 (207–208)
Savings of primary treatment costs, $ 128
Savings of continuous care, $ 39
Savings of terminal treatment, $ 46
Total induced savings, $ (95% CI) 213 (221–210)
Net costs, $ (95% CI) −5 (−13 to −2)
Life-years gained per 1000 persons 28
B. Results of alternative models
Variant
Total
costs, $
Total induced
savings, $
Net
costs, $
Expert model 208 213 −5
Alternative models
Constant dwelling time 200 437 −236
10 y of dwelling time of progressive lesions and 70% of
cancers preceded by adenomas
195 137 +58
Low screening and surveillance costs 103 213 −110
High screening and surveillance costs 386 213 +173
*95% CI 4 95% confidence interval (because of stochastic output).
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screening test characteristics or the costs
and benefits of treatment occur in the fu-
ture, the economic implications of the
screening policy would need to be recon-
sidered. If screening test characteristics
improve or screening tests become
cheaper, net savings would increase,
while better or cheaper treatment would
make screening less worthwhile. Indi-
vidual health-care provider organizations
might find the prospect of cost savings in
the relatively distant future less compel-
ling, especially if the cost savings are
likely to be realized by a public program
such as Medicare rather than the private
health provider who finances screening.
However, these problems of time horizon
of health benefits are shared by other pre-
ventive health programs as well. Further-
more, even if colorectal cancer screening
does not save costs from the perspective
of private health-care provider organiza-
tions, it may still be worthwhile because
the effects are likely to be large and the
costs relatively small, resulting in a favor-
able cost-effectiveness ratio.
The results should be seen as prelimi-
nary because considerable uncertainty
currently exists about the progression of
precursor lesions. Better estimates of the
distribution of the sojourn time of pro-
gressive adenomas and the sensitivity of
endoscopic tests will be available after
analysis of the results of endoscopic
screening trials (19,20,49) in coming
years. Meanwhile, the assumptions in the
presented model are being validated
against data from other colorectal cancer
screening studies, such as the Minnesota
Cancer Control Study of Fecal Occult
Blood Screening (7), the Kaiser program
of sigmoidoscopy screening in Northern
California (36), and the National Polyp
Study of Colonoscopic Surveillance
(50,51). The validation studies are ex-
pected to provide more information
about the natural history of colorectal
cancer and thus about the potential sav-
ings in treatment costs that are brought
about by removal of the preceding ade-
noma.
The present results also depend on the
relatively low unit costs of sigmoidosco-
py and colonoscopy. We believe that
these unit cost assumptions are plausible,
especially within the context of a screen-
ing program designed to be based on ded-
icated screening and follow-up clinics, as
in the Prostate, Lung, Colorectal and
Ovarian Cancer Screening Trial of the
NCI (52). When screening is introduced
on a large scale, the tests could also be
delivered by mid-level health profession-
als (53). In our baseline model, cost sav-
ing no longer occurs at procedure costs
that are double our base case, of similar
magnitude to those incurred in a tradi-
tional low-volume office setting (42).
This result underlines the need to investi-
gate the true cost of sigmoidoscopy and
colonoscopy in organized high-volume
settings (19,36,52). Our results are based
on an idealized screening policy with
100% screening compliance of the popu-
lation. If compliance is lower, screening
induces the same amount of costs and
savings per screenee as in the 100% com-
pliance model, as long as compliers do
not differ systematically. If noncompliers
occasionally comply, the balance of costs
and savings is more favorable because
less intensive screening results in a more
favorable cost-savings balance. We have
not considered the out-of-pocket and time
costs incurred by individuals to undergo
screening and diagnostic procedures, as
recommended by Gold et al. (13) or the
perhaps considerable savings of such
costs due to avoidance of cancer treat-
ment for some screened individuals. Nor
have we considered the costs associated
with the promotion of screening. In an
efficiently designed screening program,
such costs should be a fraction of the
costs of the initial screening procedures
costs; however, there is, to date, little
documented information on the actual
magnitude of promotional costs for colo-
rectal cancer screening.
The diagnostic follow-up and surveil-
lance protocols incorporated into the ex-
pert model are consistent with the results
of the National Polyp Study (50) and cur-
rent practice guidelines (6). These are ar-
eas of continuing clinical controversy,
and it is likely that current practice is
more aggressive than is assumed in our
model. However, there is little documen-
tation of the variation in current practice.
Future modeling work, taking advantage
of emerging data in this area (53), may be
useful in clarifying the trade-off between
economic savings and clinical risk when
comparing alternative approaches to diag-
nostic follow-up and surveillance. We
have not attempted to determine what an
optimally efficient program might be in
terms of different ages of initiating and
terminating screening, differential recruit-
ment of higher risk populations, or com-
binations of several endoscopic screening
modalities by age. More detailed model-
ing may possibly reveal a screening strat-
egy that is more efficient under baseline
assumptions than the one we have mod-
eled.
The costs of colorectal cancer screen-
ing have also been assessed in other mod-
els (11,12,41,43,54,55), two of which
assessed the costs and savings of sigmoid-
oscopy screening. None of these studies
found negative costs of screening, and all
concluded that screening may be cost-
effective. Our conclusions about the po-
tential cost savings of endoscopic screen-
ing are not inconsistent with other
modeling results when differences in as-
sumptions and structure are taken into ac-
count.
According to the model of the Office
of Technology Assessment of the U.S.
Congress (41,55), every 5-year sigmoid-
oscopy screenings after age 50 years gen-
erate 5% discounted net costs of $378 per
screened person, assuming that only 70%
of the cancers are preceded by adenomas
and that the mean duration of progressive
adenomas is 10 years. This percentage is
higher than our 3% discounted net costs
estimate of $58 per person in the whole
population when we assume the same per-
centage of cancers preceded by adenomas
and the same mean duration of progres-
sive adenomas. If we use the same dis-
count rate of 5% and calculate the costs
per person in the screening ages, our es-
timate is $271. Furthermore, in the Office
of Technology Assessment model, more
latent cancers (i.e., preclinical cancers
that would never have been clinically di-
agnosed) are detected by screening than
in our model. Lieberman (43) assessed
the costs of sigmoidoscopy screening at
age 55 years followed by another sig-
moidoscopy at age 60 years if the first
screening was negative. He found net
costs of this screening program of $1355
per screenee compared with $677 costs of
colorectal cancer treatment without
screening, resulting in $678 net costs of
screening. These net costs are high com-
pared with our estimated net costs and are
explained by the high unit costs in the
Lieberman model: $1000 for colonoscopy
without polypectomy, $1500 with polyp-
ectomy, and $150 for screening sigmoid-
oscopy.
This study shows that endoscopic co-
lorectal cancer screening has the potential
to be cost saving. The preliminary results
of this study support the importance of
ongoing and newly initiated endoscopic
screening trials.
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APPENDIX
Participants in MISCAN–COLON Expert
Model Meetings: Marjolein van Ballegooijen,
Rob Boer, J. D. F. Habbema, Franka Loeve
(Erasmus University, Rotterdam, The Nether-
lands); Martin L. Brown, Eric J. Feuer, Julie
Legler (National Cancer Institute, Bethesda,
MD); Timothy R. Church (University of Min-
nesota, Minneapolis); Chris J. Colby, Joseph
V. Selby (Kaiser Permanente, Northern Cali-
fornia); Paul A. Fishman, Margaret Mandelson
(Center for Health Studies, Group Health Co-
operative of Puget Sound); Matthew Gable,
Nicole Urban (Fred Hutchinson Cancer Re-
search Center, Seattle, WA); Bernard Levin
(The University of Texas M. D. Anderson
Cancer Center, Houston); David A. Lieberman
(Portland Veterans Administration Medical
Center, OR); Scott Ramsey (University of
Washington, Seattle); Judith L. Wagner (Con-
gressional Budget Office); and Ann G. Zauber
(Memorial Sloan-Kettering Cancer Center,
New York, NY).
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Registry data are submitted electronically without
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and the NCI makes the data available to the public
for scientific research.
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